http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106609262-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b59310b55a6488e1df963cd951a9ab2e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0735 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-077 |
| filingDate | 2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c13076e314ebd2637922fbf3fd769ce3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8631be9b74c3740f77a908a096d7860 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_837c5747b78722df1b6268babb7b929f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa87c7cdf7180c8fa44aaed5939be70a |
| publicationDate | 2017-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106609262-A |
| titleOfInvention | Method used for increasing efficiency of differentiation of umbilical cord derived stem cells into cardiac muscle cells |
| abstract | The invention belongs to the technical field of biological cell, and more specially relates to a method used for increasing efficiency of in vitro directional induction differentiation of umbilical cord derived stem cells into cardiac muscle cells. According to the method, basic fibroblast growth factor and transforming growth factor-beta1 of a certain concentration are added into an umbilical cord derived stem cell-cardiac muscle cell directional induction differentiation culturing solution so as to obtain about 50 to 70% cardiac-like muscle cells. Compared with pure 5-azacytidine induction (differentiation efficiency is about 30%), differentiation efficiency is increased obviously. In vitro proliferation capacity of cardiac muscle cells is limited, and requirements of in vitro construction of tissue engineering cardiac muscle are not satisfied, so that the novel method used for acquiring cardiac muscle cells rapidly is provided; supply resources are provided for cardiac muscle cell damages, foundation is provided for treatment of myocardial infarction and end-stage cardiac insufficiency via stem cell transplantation, and clinical application prospect is promising. |
| priorityDate | 2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 128.